Guselkumab

• Plaque Psoriasis
• Psoriatic Arthritis
• Moderate to Severe Psoriasis
• IL-23 Inhibitor Therapy

Guselkumab is a fully human monoclonal antibody that selectively blocks interleukin-23, used to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis. It belongs to a newer class of biologics — the IL-23 p19 inhibitors — that target the upstream driver of Th17-mediated inflammation while sparing other arms of the immune system. For patients whose psoriatic disease has not responded adequately to topical agents, phototherapy, or conventional systemic agents such as methotrexate, guselkumab offers high rates of skin clearance and meaningful improvement in joint symptoms with a relatively favorable safety profile. It is one of several options reviewed within dermatologic and rheumatologic care.

Mechanism of Action

Guselkumab is an IgG1 lambda monoclonal antibody that binds with high affinity to the p19 subunit of interleukin-23, preventing IL-23 from engaging the IL-23 receptor complex on the surface of T cells, innate lymphoid cells, and other immune cells. IL-23 is the master regulator of the Th17 immune axis, a pathway central to the pathogenesis of plaque psoriasis and psoriatic arthritis. When IL-23 signaling is intact, naive T cells differentiate into pathogenic Th17 cells that produce IL-17A, IL-17F, IL-22, and tumor necrosis factor — cytokines that drive keratinocyte hyperproliferation, neutrophil recruitment to skin, synovial inflammation, and enthesitis.

By selectively targeting the p19 subunit, guselkumab leaves IL-12 (which shares the p40 subunit with IL-23) untouched, preserving Th1 immune function important for defense against intracellular pathogens. This selectivity is thought to underlie the relatively low rate of serious infections compared with broader immunosuppressants. After subcutaneous injection, guselkumab is slowly absorbed, with peak serum concentrations reached around 5 to 6 days. Steady-state concentrations are achieved by week 20 of dosing. The half-life is roughly 15 to 18 days, supporting an every-8-week maintenance dosing schedule. Clinical effect on psoriasis plaques typically begins within 4 to 8 weeks, with maximum response at 16 to 24 weeks. Joint symptoms in psoriatic arthritis may take 12 to 24 weeks to reach peak benefit.

Clinical Use

Guselkumab is FDA-approved for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and for adults with active psoriatic arthritis. Treatment guidelines from the American Academy of Dermatology and the National Psoriasis Foundation position IL-23 inhibitors among preferred first-line biologics for moderate-to-severe psoriasis, alongside IL-17 inhibitors such as secukinumab and ixekizumab. Pivotal psoriasis trials showed that approximately 70 to 85 percent of patients achieved a 90 percent improvement in PASI scores at 16 weeks, with sustained responses through 5 years.

For psoriatic arthritis, guselkumab improves joint symptoms, enthesitis, dactylitis, skin clearance, and physical function. It is a reasonable option for patients with prominent skin disease, those who failed or do not tolerate TNF inhibitors such as adalimumab or etanercept, and those who prefer less frequent injections. Compared with TNF inhibitors, IL-23 inhibitors have a lower rate of serious infections, no apparent increase in tuberculosis reactivation when latent disease is treated, and no signal for new-onset demyelinating disease. Compared with IL-17 inhibitors, IL-23 inhibitors are dosed less frequently and may be preferred in patients with inflammatory bowel disease history, since IL-17 blockade has been associated with IBD flares. Evidence-based recommendations are summarized at aad.org.

How to Take It

Guselkumab is administered as a 100 mg subcutaneous injection at weeks 0 and 4, then every 8 weeks thereafter. The medication is supplied in a prefilled syringe or the One-Press patient-controlled injector, which many patients prefer for ease of use. Injections are given in the front of the thigh, the abdomen at least 2 inches from the navel, or the upper outer arm if administered by a caregiver. Sites should be rotated to minimize injection-site reactions.

Guselkumab requires refrigeration between 36°F and 46°F (2°C to 8°C) but can be kept at room temperature up to 77°F (25°C) for up to 30 days. The drug should not be shaken or frozen, and the syringe should be allowed to reach room temperature for about 30 minutes before injection — cold injections sting more. Patients self-injecting should follow the manufacturer's training materials carefully and dispose of used devices in an approved sharps container. If a dose is missed, it should be administered as soon as remembered, and the regular schedule resumed from that point. The first 2 to 4 weeks of therapy may bring mild injection-site soreness or redness; significant systemic responses are uncommon. Patients should not receive live vaccines during therapy.

Monitoring and Follow-Up

Before starting guselkumab, all patients should be screened for latent and active tuberculosis using an interferon-gamma release assay or tuberculin skin test, along with a chest X-ray if exposure history is concerning. Patients with latent TB require treatment before initiating biologic therapy. Hepatitis B and C screening is also standard. Vaccination status should be reviewed and brought up to date — particularly inactivated influenza, pneumococcal, and shingles vaccines — before starting therapy, since live vaccines must be avoided during treatment.

No routine laboratory monitoring is mandated by the FDA label, but periodic complete blood count, liver function tests, and clinical assessment for infection are reasonable. The most important monitoring is clinical: PASI score or body surface area assessment for psoriasis, and tender/swollen joint counts plus enthesitis indices for psoriatic arthritis. Response is typically evaluated at week 16; non-responders should be considered for switching therapy. Annual TB re-screening is appropriate for patients in high-risk settings. Watch for signs of infection — persistent cough, unexplained fever, night sweats, or weight loss — and rare reports of new-onset inflammatory bowel disease. The CDC vaccination guidance at cdc.gov is a useful reference.

Special Populations

Elderly patients did not show meaningfully different safety or efficacy in trials, but the higher baseline infection risk in this group warrants extra vigilance. No dose adjustment is needed for renal or hepatic impairment, since monoclonal antibodies are catabolized by general protein degradation rather than hepatic or renal clearance. Pregnancy data are limited; animal studies showed no developmental toxicity. IgG antibodies cross the placenta in the second and third trimesters, so infants exposed in utero should not receive live vaccines for at least 6 months after birth. Use during pregnancy is individualized to disease severity and benefit-risk balance.

Guselkumab presence in human breast milk is unknown. Maternal IgG passes into milk in low amounts and is largely degraded in the infant gut, suggesting low risk; the decision to breastfeed should consider maternal need and infant exposure. Pediatric safety and efficacy have not been established. Patients with significant cardiovascular disease such as coronary artery disease deserve careful evaluation before any biologic, though no specific cardiovascular contraindication exists.

When to Contact Your Doctor

Seek immediate care for signs of serious infection — high fever, shaking chills, productive cough, painful urination, severe abdominal pain, or sudden mental status change. Persistent unexplained cough, night sweats, or weight loss may signal reactivation of tuberculosis. Sudden swelling of the face, tongue, or throat, hives, or difficulty breathing after an injection may indicate a hypersensitivity reaction and warrants emergency evaluation. New or worsening abdominal pain, persistent diarrhea, or bloody stools could suggest inflammatory bowel disease and should be evaluated promptly. Significant injection-site reactions that worsen rather than improve, new neurologic symptoms such as numbness, weakness, or visual changes, and any unexplained skin lesions deserve prompt review. If you become pregnant or plan to become pregnant during therapy, discuss the timing and balance of treatment with your clinician.

Patients planning international travel — particularly to regions with endemic infections such as tuberculosis, fungal infections, or certain parasitic diseases — should discuss timing of injections and any special precautions. Sudden severe headache with neck stiffness, photophobia, or altered consciousness might rarely indicate central nervous system infection and demands emergency evaluation. New unexplained weight loss, drenching night sweats, or persistent low-grade fever lasting more than a week should not be ignored, since IL-23 blockade may slightly increase the risk of certain infections and rare malignancies. Annual skin examinations are reasonable for patients on long-term immunomodulatory therapy.

If you have been recommended a biologic for psoriasis or psoriatic arthritis and want a thorough discussion of options including guselkumab, contact us or schedule a visit with our team to develop a tailored treatment plan.